Company Description
Anavex Life Sciences Corp. operates as a biopharmaceutical company.
It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome.
Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors.
The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies.
Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Christopher Missling |
Contact Details
Address: 630 5th Avenue, 20th Floor New York, New York 10111 United States | |
| Phone | 844 689 3939 |
| Website | anavex.com |
Stock Details
| Ticker Symbol | AVXL |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001314052 |
| CUSIP Number | 032797300 |
| ISIN Number | US0327973006 |
| Employer ID | 98-0608404 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Sandra Boenisch CPA, CGA | Principal Financial Officer and Treasurer |
| Clint Tomlinson | Vice President of Corporate |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Dr. Kun Jin Ph.D. | Head of Biostatistics |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior Vice President and Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 28, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 424B5 | Filing |
| Jul 23, 2025 | EFFECT | Notice of Effectiveness |
| Jul 14, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 3, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |